Skip to main content

Multiple Sclerosis Drugs Market to Hit USD 40.66 Bn by 2027; Promising Research into Developing Efficient MS Therapies to Prove Beneficial for the Market: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, July 30, 2020 (GLOBE NEWSWIRE) — The global multiple sclerosis drugs market size is projected to reach USD 40.66 billion by 2027, exhibiting a CAGR of 7.1% during the forecast period. High prevalence of multiple sclerosis (MS) worldwide will be the primary factor driving the growth of this market, states Fortune Business Insights™ in its report, titled “Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027”. https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
Quantitative insights on the market values (size, share, revenue, etc.);Qualitative analysis of the factors driving the market growth;Thorough study of the market restraints;Detailed examination of the market segments; andComprehensive assessment of the regional developments and competitive landscape of the market.The global economy has plunged into turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, and some are in serious trouble. The healthcare industry is experiencing mixed impact of this pandemic. Navigating through these challenging times is a mammoth task and to aid you in your journey, Fortune Business Insights™ aims at equipping your business with the most comprehensive market intelligence, collated and analyzed by our expert and experienced research team.Please visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
Availability of Monoclonal Antibodies for MS Treatment to Favor Market GrowthMonoclonal antibodies, as the name suggests, are clones of a specific antibody, which are developed as multiple sclerosis drug treatments. Their most notable feature is that they can tailor the immune system response to MS by binding to specific, targeted proteins on the body’s normal cells. Thus, these antibody treatments can be designed to deliver a highly specific effect in a patient. More importantly, there is growing availability of monoclonal antibodies, with some treatments being more widely used than others.For instance, Roche’s Ocrevus antibody, which binds to and destroys B-cells, has been extensively adopted as an MS treatment since it received FDA approval in 2017. Similarly, Sanofi’s Lemtrada, which binds to proteins on white blood cells, has been available in the market since 2014, when it secured clearance from the FDA. Rising popularity of monoclonal antibodies is, therefore, proving critical in fueling the multiple sclerosis drugs market growth.Regional InsightsHealthy Awareness about MS to Feed Market Growth in North AmericaNorth America boasted a market size of USD 14.74 billion in 2019 on account of widespread awareness about MS and its treatments. In the US, government bodies such as the Multiple Sclerosis Association of America conducts educational drives during the month of March, which is recognized as the Multiple Sclerosis Awareness Month in the country.Europe is expected to hold a prominent position in the multiple sclerosis drugs market share during the forecast period owing to supportive health reimbursement policies. In Asia Pacific, the market is anticipated to perform remarkably well as pharmaceutical companies are aggressively expanding their distribution networks across the region.Strong Regulatory Support for Novel MS Therapies to Spur CompetitionKey players in this market are receiving strong encouragement and support from regulatory authorities to develop novel multiple sclerosis drugs and therapies. In response, companies are doubling down their investment in R&D in an attempt to cater to the growing demand for MS treatments from patients globally.Industry Developments:May 2020: Bristol Myers Squibb announced that its Zeposia drug, an oral medication for treating relapsing multiple sclerosis in adult patients received approval from the European Commission (EC). The marketing authorization from the EC will enable the company to broaden its presence in Europe.March 2019: The US FDA gave its nod to Mayzent (siponimod), developed by Novartis to treat adults with relapsing forms of MS. The treatment will be able to treat relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) with active disease.Bristol-Myers Squibb Company (New York, U.S.)Sanofi (Paris, France)Novartis AG (Basel, Switzerland)Pfizer Inc. (New York, U.S.)Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)Merck & Co., Inc. (New Jersey, U.S.)F. Hoffmann-La Roche Ltd. (Basel, Switzerland)Biogen (Massachusetts, U.S.)IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Multiple Sclerosis – For Key CountriesRegulatory & Reimbursement Overview – For Key CountriesPipeline AnalysisPatent SnapshotNew Product LaunchesKey Industry Developments – Mergers, Acquisitions and PartnershipsGlobal Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By Drug ClassImmunomodulatorsImmunosuppressantsInterferonsOthersMarket Analysis, Insights and Forecast – By Route of AdministrationOralInjectionIntramuscularSubcutaneousIntravenousMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaTOC Continued…!!!
Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2019-2026Cancer Cachexia Market Size, Share & Covid-19 Impact Analysis, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027Wound Care Market Size, Share & Covid-19 Impact Analysis, By Type (Advanced Wound Dressing, Traditional Wound Care Products, Negative Pressure Wound Therapy, Bioactives, and Others), By Application (Chronic Wounds, and Acute Wounds), By End User (Hospitals, Clinics, Homecare Settings, and Others), and Regional Forecast, 2020-2027COVID-19 Diagnostics Market Size, Share & Industry Analysis, By Product (Instruments and Reagents & Kits), By Technology (PCR (Polymerase Chain Reaction), ELISA (Enzyme-linked Immunosorbent Assay), Point-of-care (POC), and Others), By Sample Type (Oropharyngeal and Nasopharyngeal Swabs, Blood, Urine, and Others), By End User (Hospitals & Clinics, Laboratories & Diagnostic Centers, and Research Institutes), and Regional Forecast, 2020-2027Dental Materials Market Size, Share & COVID-19 Impact Analysis, By Type (Metallic Biomaterials, Ceramic Biomaterials, Polymers, Natural Biomaterials, and Others), By Application (Implant, Prosthetics, and Orthodontics), By End User (Dental Product Manufacturers, Dental Laboratories, and Others), and Regional Forecast, 2020-2027About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/multiple-sclerosis-drugs-market-9105

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.